---
title: "Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Thursday When Compared To Competitors"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286470627.md"
description: "Corbus Pharmaceuticals Holdings Inc. (CRBP) shares fell 1.40% to $11.98 on Thursday, ending a four-day winning streak, despite a strong overall market performance. The NASDAQ Composite rose 0.88% and the Dow Jones increased by 0.75%. Corbus's stock is currently 41.73% below its 52-week high of $20.56. In comparison, competitors Vanda Pharmaceuticals, Fortress Biotech, and Viking Therapeutics had mixed performances, with Fortress Biotech seeing a notable rise of 3.14%."
datetime: "2026-05-14T21:20:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286470627.md)
  - [en](https://longbridge.com/en/news/286470627.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286470627.md)
---

# Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Thursday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Corbus Pharmaceuticals Holdings Inc. (CRBP) slipped 1.40% to $11.98 Thursday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ Composite Index rising 0.88% to 26,635.22 and the Dow Jones Industrial Average rising 0.75% to 50,063.46.

The stock's fall snapped a four-day winning streak.

Corbus Pharmaceuticals Holdings Inc. closed 41.73% short of its 52-week high of $20.56, which the company achieved on October 20th.

The stock underperformed when compared to some of its competitors Thursday, as Vanda Pharmaceuticals Inc. (VNDA) fell 0.62% to $6.39, Fortress Biotech Inc. (FBIO) rose 3.14% to $2.30, and Viking Therapeutics Inc. (VKTX) rose 0.03% to $31.71.

Trading volume (217,857) remained 47,095 below its 50-day average volume of 264,952.

Data source: Dow Jones Market Data, FactSet. Data compiled May 14, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

05-14-26 1720ET

### Related Stocks

- [CRBP.US](https://longbridge.com/en/quote/CRBP.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [.IXIC.US](https://longbridge.com/en/quote/.IXIC.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)
- [VNDA.US](https://longbridge.com/en/quote/VNDA.US.md)
- [FBIO.US](https://longbridge.com/en/quote/FBIO.US.md)
- [VKTX.US](https://longbridge.com/en/quote/VKTX.US.md)
- [FBIOP.US](https://longbridge.com/en/quote/FBIOP.US.md)

## Related News & Research

- [Corbus Pharmaceuticals (CRBP) Receives a Buy from LifeSci Capital](https://longbridge.com/en/news/286648720.md)
- [RBC Capital Reaffirms Their Buy Rating on Corbus Pharmaceuticals (CRBP)](https://longbridge.com/en/news/286342985.md)
- [Brokers Offer Predictions for CRBP Q2 Earnings](https://longbridge.com/en/news/286408539.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [Corvus Pharmaceuticals presents Phase 1 soquelitinib data showing durable remissions, favorable safety](https://longbridge.com/en/news/286404245.md)